title: First-to-patent does not predict first- or best-in-class: analysis of approved small molecule vs. biologic drugs.
abstract: The biopharmaceutical enterprise continues to analyze, refine, and identify key strategic factors predicting success of innovative therapeutic advances to address important unmet medical needs. A key comparison has focused on the relative benefits of the novel mechanism of a first-in-class drug vs. the superior properties that differentiate improved follow-on drugs (best-in-class). A corollary question to first-in-class vs. best-in-class is the impact of patent timing. Surprisingly, first-to-patent does not predict first- or best-in-class.
authors: Scientific Knowledge Discovery, Merck & Co., Inc, Whitehouse Station, New Jersey, USA.
authors: G E
authors: GE
authors: Roland
authors: J J
authors: JJ
authors: Xu
authors: J A
authors: JA
authors: Wagner
mesh_terms: D001688:Biological Products / Q000494:pharmacology / Q000627:therapeutic use*; D017277:Drug Approval; D015195:Drug Design; D004345:Drug Industry / Q000379:methods* / Q000706:statistics & numerical data; D006301:Health Services Needs and Demand; D006801:Humans; D010330:Patents as Topic / Q000706:statistics & numerical data*; D013997:Time Factors
chemical_list: D001688:Biological Products